Cambridge drug developer Tiburio launches, targeting pituitary tumors with $31M

A Cambridge startup hoping to develop the first drug treatments to shrink dangerous tumors on the brain's pituitary gland launched Thursday with $31 million in funding. Tiburio Therapeutics Inc. was spun out of Cambridge orphan disease accelerator Cydan this week with the Series A funding from New Enterprise Associates, Longitude Capital and Alexandria Real Estate Equities Inc.'s (NYSE: ARE) venture arm, Alexandria Venture Investments. Ibsen, which moved its U.S. headquarters to Massachusetts last…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Source Type: news